K. Martin Kortüm

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 772 citations

Hematological Malignancy, Medicine, Pathology +6

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Matteo Da Vià, Oliver Dietrich, Marietta Truger et al. · Nature Medicine · 2021 · 314 citations

Hematological Malignancy, Autoimmune Disease, Malignant Blood Disorder +8

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

Holly Lee, Sungwoo Ahn, Ranjan Maity et al. · Nature Medicine · 2023 · 280 citations · Full text

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

K. Martin Kortüm, K. Elias, Nur Hafzan Md Hanafiah et al. · Blood · 2016 · 243 citations · Full text

[⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values

Constantin Lapa, Martin Schreder, Andreas Schirbel et al. · Theranostics · 2016 · 188 citations · Full text